Systemic beta-interferon therapy for recurrent gliomas: a brief report.
Recombinant beta-interferon in escalating dosages was administered intravenously three times weekly to seven patients with recurrent gliomas. No evidence of response was seen in any patient, either on neurological examination or by computerized tomography (CT). However, stabilization of tumor volume, assessed from contrast-enhanced CT scans, occurred for 8 to 26 weeks in three patients. Immediate progression of disease despite treatment occurred in four patients.
Mahaley
M S
MS
Division of Neurological Surgery, University of Alabama, Birmingham.
Dropcho
E J
EJ
Bertsch
L
L
Tirey
T
T
Gillespie
G Y
GY
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000628:therapy*; D005910:Glioma / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*
D007370:Interferon Type I; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a